Savant Capital LLC Increases Stock Holdings in Gilead Sciences, Inc. $GILD

Savant Capital LLC raised its position in Gilead Sciences, Inc. (NASDAQ:GILD) by 67.5% in the 2nd quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission (SEC). The institutional investor owned 49,086 shares of the biopharmaceutical company’s stock after acquiring an additional 19,777 shares during the quarter. Savant Capital LLC’s holdings in Gilead Sciences were worth $5,442,000 as of its most recent SEC filing.

Other institutional investors and hedge funds also recently bought and sold shares of the company. One Wealth Advisors LLC lifted its holdings in shares of Gilead Sciences by 34.8% in the 2nd quarter. One Wealth Advisors LLC now owns 9,163 shares of the biopharmaceutical company’s stock valued at $1,016,000 after purchasing an additional 2,364 shares during the last quarter. Ariel Investments LLC lifted its stake in Gilead Sciences by 7.7% in the first quarter. Ariel Investments LLC now owns 430,424 shares of the biopharmaceutical company’s stock valued at $48,229,000 after buying an additional 30,630 shares during the last quarter. Wealth Management Associates Inc. acquired a new stake in shares of Gilead Sciences in the second quarter valued at approximately $255,000. Sivik Global Healthcare LLC grew its position in shares of Gilead Sciences by 25.0% during the second quarter. Sivik Global Healthcare LLC now owns 50,000 shares of the biopharmaceutical company’s stock worth $5,544,000 after acquiring an additional 10,000 shares during the last quarter. Finally, Covea Finance increased its holdings in shares of Gilead Sciences by 69.5% in the 2nd quarter. Covea Finance now owns 51,700 shares of the biopharmaceutical company’s stock valued at $5,732,000 after acquiring an additional 21,200 shares during the period. 83.67% of the stock is currently owned by hedge funds and other institutional investors.

Analyst Upgrades and Downgrades

A number of analysts recently weighed in on GILD shares. Wolfe Research increased their price target on shares of Gilead Sciences from $135.00 to $140.00 and gave the stock an “outperform” rating in a research note on Thursday, October 23rd. TD Cowen increased their target price on shares of Gilead Sciences from $115.00 to $125.00 and gave the stock a “buy” rating in a research note on Thursday, October 23rd. Weiss Ratings restated a “buy (b)” rating on shares of Gilead Sciences in a research report on Wednesday, October 8th. Wells Fargo & Company upped their price objective on Gilead Sciences from $140.00 to $145.00 and gave the company an “overweight” rating in a research note on Friday, October 31st. Finally, Dbs Bank upgraded Gilead Sciences to a “moderate buy” rating in a research note on Friday, September 5th. One analyst has rated the stock with a Strong Buy rating, twenty-two have assigned a Buy rating and three have given a Hold rating to the company’s stock. According to data from MarketBeat.com, Gilead Sciences presently has a consensus rating of “Moderate Buy” and an average price target of $127.82.

Gilead Sciences Stock Performance

NASDAQ GILD opened at $118.84 on Friday. The stock has a market capitalization of $147.46 billion, a price-to-earnings ratio of 23.67, a PEG ratio of 0.81 and a beta of 0.32. The business’s 50 day moving average is $116.49 and its two-hundred day moving average is $112.22. Gilead Sciences, Inc. has a 12-month low of $86.08 and a 12-month high of $124.61. The company has a current ratio of 1.32, a quick ratio of 1.15 and a debt-to-equity ratio of 1.13.

Gilead Sciences (NASDAQ:GILD) last posted its quarterly earnings results on Thursday, October 30th. The biopharmaceutical company reported $2.47 EPS for the quarter, beating the consensus estimate of $2.16 by $0.31. Gilead Sciences had a return on equity of 50.99% and a net margin of 21.86%.The business had revenue of $7.77 billion during the quarter, compared to analysts’ expectations of $7.42 billion. During the same period last year, the firm earned $2.02 EPS. The company’s quarterly revenue was up 3.0% compared to the same quarter last year. Gilead Sciences has set its FY 2025 guidance at 8.050-8.250 EPS. Research analysts expect that Gilead Sciences, Inc. will post 7.95 EPS for the current year.

Gilead Sciences Announces Dividend

The business also recently announced a quarterly dividend, which will be paid on Tuesday, December 30th. Shareholders of record on Monday, December 15th will be given a dividend of $0.79 per share. This represents a $3.16 annualized dividend and a dividend yield of 2.7%. The ex-dividend date is Monday, December 15th. Gilead Sciences’s payout ratio is presently 48.99%.

Insider Transactions at Gilead Sciences

In other news, CEO Daniel Patrick O’day sold 10,000 shares of the stock in a transaction dated Monday, September 29th. The shares were sold at an average price of $111.66, for a total value of $1,116,600.00. Following the completion of the transaction, the chief executive officer owned 591,203 shares in the company, valued at $66,013,726.98. This trade represents a 1.66% decrease in their position. The sale was disclosed in a document filed with the SEC, which is available through this hyperlink. Also, insider Johanna Mercier sold 28,000 shares of the firm’s stock in a transaction dated Friday, August 15th. The shares were sold at an average price of $118.53, for a total transaction of $3,318,840.00. Following the completion of the sale, the insider owned 114,168 shares of the company’s stock, valued at $13,532,333.04. This trade represents a 19.70% decrease in their position. The disclosure for this sale is available in the SEC filing. Insiders have sold a total of 71,500 shares of company stock valued at $8,336,040 in the last ninety days. 0.27% of the stock is currently owned by company insiders.

About Gilead Sciences

Gilead Sciences, Inc, a biopharmaceutical company, discovers, develops, and commercializes medicines in the areas of unmet medical need in the United States, Europe, and internationally. The company provides Biktarvy, Genvoya, Descovy, Odefsey, Truvada, Complera/ Eviplera, Stribild, Sunlencs, and Atripla products for the treatment of HIV/AIDS; Veklury, an injection for intravenous use, for the treatment of COVID-19; and Epclusa, Harvoni, Vemlidy, and Viread for the treatment of viral hepatitis.